A pooled analysis by Akinboro O and colleagues evaluated the outcomes of patients with advanced NSCLC who had high PD-L1 expression (≥50%) and received either chemotherapy combined with immune checkpoint inhibitors (chemo-ICI) or ICIs alone. Here, CD274 is linked to non-small cell lung carcinoma.